Our discovery and development teams are working to identify and advance into the clinic, novel Live Biotherapeutic Products to help patients with infectious, inflammatory, and oncologic diseases.
Tackling the biggest global health threats
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world.
Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such as organ transplantations, chemotherapy and surgeries such as caesarean sections become much more dangerous.
The Artugen team has discovered and is developing a novel oral Live Biotherapeutic Product for the prevention of C. difficile infection recurrence.
Have a question?
Interested in collaborating with us?